Yüklüyor......
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
BACKGROUND AND OBJECTIVES: Risankizumab is a humanized anti-interleukin-23 monoclonal antibody in development for the treatment of several inflammatory diseases. This work characterized the pharmacokinetics of risankizumab and evaluated covariates that may affect its exposures using phase I and II t...
Kaydedildi:
| Yayımlandı: | Clin Pharmacokinet |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer International Publishing
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6373392/ https://ncbi.nlm.nih.gov/pubmed/30123942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0704-z |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|